Dr. Nasser Hanna discusses the SQUIRE trial of the EGFR antibody Necitumumab in patients with squamous lung cancer. Though it achieved a statistical increase in OS, he does not consider it clinically relevant.
GRACE, cancerGRACE, GRACEcast, advanced NSCLC, Rosalyn Juergens, McMaster University, molecular oncology, targeted therapy, NSCLC histology, Canada
Dr. Rosalyn Juergens: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?
Dr. Sarah Goldberg on "Which molecular marker tests do you seek?"
Dr. Heather Wakelee on "My Approach to Maintenance Therapy for Advanced NSCLC"
Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis (video)
Dr. Ravi Salgia: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?
Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 1): Potential Value of Molecular Staging (video)
Dr. Karen Kelly: My Approach to Repeat Biopsies For Advanced NSCLC Patients Who Have Insufficient Tissue for Molecular Testing
Dr. David Spigel: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?
Dr. Rosalyn Juergens: Recommending a Repeat Biopsy with Acquired Resistance to a Targeted Therapy
Dr. Sarah Goldberg on "I Just Found Out I Have an EGFR Mutation, and I'm in the Middle of Chemo. What Now?"
Dr. Greg Riely on "My Approach to Maintenance Therapy for Advanced NSCLC"
Dr. Phil Bonomi, How Do I Discuss the Side Effects of Targeted Therapies, as Compared with Chemotherapy?
Drs. Ross Camidge and Corey Langer on "Which patients do you send molecular marker testing for, and what tests do you seek?"
Dr. Ravi Salgia on the CollabRx System for Matching Patients with Mutations to Clinical Trials
Dr. Geoffrey Oxnard on the Most Promising Upcoming New Targeted Agents and Molecular Pathways for Lung Cancer Treatment
Dr. Karen Kelly: Do You Continue a Treatment Beyond 4-6 Cycles to Exhaust its Benefit?
Dr. David Spigel: How Do You Discuss the Pros and Cons of Molecular Testing, with Potential Delays and Need for Rebiopsy?
Dr. Sarah Goldberg: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?
Dr. Lecia Sequist on Multiplex Next Generation Sequencing and its Effect on Molecular Oncology Practice
Create your
podcast in
minutes
It is Free
Good Mood Revolution
GRACEcast Pancreatic Cancer Audio
GRACEcast Radiation Oncology Audio
GRACEcast Head and Neck Cancer Video NEW
GRACEcast Kidney Cancer Video
GRACEcast Social Work and Coping Video